Comparative Antihypertensive Effects of Guanabenz and Clonidine

No abstract is available for this paper.

• Publication year

  1982

• Venue

  Journal of International Medical Research

• Publication date

  1982-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/030006058201000102PMID 7037502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative antihypertensive effects of guanabenz and methyldopa.

  1981cited by this paper
• Complications of antihypertensive therapy.

  1981cited by this paper
• Long-term therapy of hypertension with guanabenz.

  1981cited by this paper
• Effects of methyldopa on renal hemodynamics and tubular function

  1980cited by this paper
• [The antihypertensive effect of 2,6-dichloro-benzylidene-aminoguanidine acetate (Guanabenz)].

  1980cited by this paper
• Clonidine and the Kidney

  1980cited by this paper
• Effects of Placebo versus Guanabenz on Hypertensive Out-Patients

  1980cited by this paper
• Pharmacology of antihypertensive drugs

  1980cited by this paper
• [Clinical experiences in antihypertensive treatment with guanabenz or clonidine in combination with thiazide].

  1978cited by this paper
• Guanabenz and methyldopa on hypertension and cardiac performance

  1977cited by this paper
• Guanabenz effects on blood pressure and noninvasive parameters of cardiac performance in patients with hypertension

  1976cited by this paper
• Studies on the centrally mediated hypotensive activity of guanabenz.

  1976cited by this paper
• Renal Effects of Guanabenz: A New Antihypertensive

  1976cited by this paper
• Evaluation of clonidine hydrochloride (Catapres). A new antihypertensive agent.

  1975cited by this paper
• Surgery's relevance to an understanding of basic biology. Tissue repair and cellular regeneration.

  1967cited by this paper

• Mammalian integrated stress responses in stressed organelles and their functions

  2024cites this paper
• Detoxification of Neuromodulation Eligible Patients by a Standardized Protocol: A Retrospective Pilot Study.

  2021cites this paper
• Aromatic Guanylhydrazones for the Control of Heme-Induced Antibody Polyreactivity

  2019cites this paper
• Direct Vasodilators and Sympatholytic Agents

  2016cites this paper
• Suppressed invasive and migratory behaviors of SW1353 chondrosarcoma cells through the regulation of Src, Rac1 GTPase, and MMP13.

  2015cites this paper
• Adaptive Capacity and Community-Based Natural Resource Management

  2005cites this paper
• Adaptive Comanagement for Building Resilience in Social–Ecological Systems

  2004cites this paper
• Therapeutic effects of evening administration of guanabenz and clonidine on morning hypertension: evaluation using home-based blood pressure measurements

  2003cites this paper
• [Antihypertensive medication and sleep].

  1998cites this paper
• Metabolic consequences of antihypertensive therapy

  1996cites this paper
• Mediation of the hypotensive action of systemic clonidine in the rat by α2‐adrenoceptors

  1993cites this paper
• Mediation of the hypotensive action of systemic clonidine in the rat by alpha 2-adrenoceptors.

  1993cites this paper
• Use of centrally acting sympatholytic agents in the management of hypertension.

  1991cites this paper
• The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension.

  1990cites this paper
• The metabolic effects of diuretics and other antihypertensive drugs: a perspective as of 1989.

  1990cites this paper
• New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension.

  1989cites this paper
• The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics.

  1988cites this paper
• The effects of antihypertensive agents on serum lipids and lipoproteins.

  1988cites this paper
• The changing face of clinical trials.

  1988cites this paper
• Tailoring antihypertensive drug therapy for the black patient.

  1987cites this paper
• Psychiatric Indications for Clonidine: The Neuropharmacologic and Clinical Basis

  1986cites this paper
• Current Therapeutic Concepts in Diabetic Hypertension

  1986cites this paper
• Guanabenz Therapy for Opiate Withdrawal

  1985cites this paper
• Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis.

  1985cites this paper
• Guanabenz for adolescent hypertension.

  1984cites this paper
• Dose‐Response Relationship of Single Oral Doses of Guanabenz in Hypertensive Patients

  1984cites this paper
• Central Nervous Sys tem‐Renal Interrelationship in Mechanism of Action of Guanabenz. Role of Peripheral α2‐Adrenoceptor Agonist Activity

  1984cites this paper
• Current assessment of the stepped-care treatment of mild hypertension: diuretics, beta-blockers, vasodilators versus Clonidine

  1984cites this paper
• Effects of Central Alpha-Adrenoceptor Agonists and Adrenergic-Neuronal Blocking Agents on the Kidney

  1984cites this paper
• Effects of Guanabenz in Adolescent Hypertension

  1984cites this paper
• Differential binding of guanabenz and its metabolites to cerebral α2‐receptors: The basis for a radioligand assay specific for the drug

  1983cites this paper
• Guanabenz (Wytensin) a new antihypertensive drug.

  1983cites this paper
• Guanabenz

  1983cites this paper